Last reviewed · How we verify

ziprasidone or olanzapine — Competitive Intelligence Brief

ziprasidone or olanzapine (ziprasidone or olanzapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

ziprasidone or olanzapine (ziprasidone or olanzapine) — Medical University of Vienna. Both ziprasidone and olanzapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ziprasidone or olanzapine TARGET ziprasidone or olanzapine Medical University of Vienna marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Aripiprazole; Quetiapine Aripiprazole; Quetiapine Taichung Veterans General Hospital marketed Atypical antipsychotic combination Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Antipsychotic Maintenance Antipsychotic Maintenance University College, London marketed Antipsychotic (typical or atypical) Dopamine D2 receptor; serotonin 5-HT2A receptor (varies by specific agent)
Risperidone tablets Risperidone tablets Sumitomo Pharma (Suzhou) Co., Ltd. marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Risperidone low dose Risperidone low dose Johnson & Johnson Pharmaceutical Research & Development, L.L.C. marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Intramuscular olanzapine, aripiprazole Intramuscular olanzapine, aripiprazole Veterans Medical Research Foundation marketed Atypical antipsychotic Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole)
Standard of Care Oral antipsychotics Standard of Care Oral antipsychotics University of Utah marketed Antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ziprasidone or olanzapine — Competitive Intelligence Brief. https://druglandscape.com/ci/ziprasidone-or-olanzapine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: